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K x-ray fluorescence (KXRF) technology has been used to make in vivo measurements of lead in bone for
more than three decades. The data obtained are beneficial to research on lead toxicity as well as, in certain
circumstances, the practice of occupational and environmental medicine. This paper reviews the impact
of KXRF data on epidemiologic research involving lead toxicity and demonstrates that bone lead is and
will continue to be a valuable biomarker in addressing long-term health effects related to cumulative
exposure. The KXRF system has been improved and upgraded several times ever since it was first used.
The consistency of the data obtained from these KXRF systems has been investigated in many studies.
This paper provides an overview of the factors that will affect the data generated by the KXRF systems.
A calibration problem encountered in one of the major KXRF laboratories is described, and the approach
taken to solve the problem is discussed. Despite all the theoretical considerations, there are still some
important practical challenges to the intercalibration of KXRF instruments both within the laboratory, and
between laboratories. Copyright  2007 John Wiley & Sons, Ltd.
INTRODUCTION
The first in vivo x-ray fluorescence (XRF) measurement of
lead in bone was made in the 1970s.1 The significance
of this technology in lead exposure assessment was then
appreciated by a group of epidemiology scientists.2 – 5 Prior
to the K x-ray fluorescence (KXRF) bone lead measurement,
blood lead measurement was widely used to monitor lead
exposure. Since bone is the primary storage organ for lead
in the human body, whereas blood reflects the current or
short-term exposure, there are some epidemiological studies
of lead expsoure for which measurement of bone lead is
preferred to that of blood lead.6,7 Bone lead has been used to
investigate the association between lead exposure and many
health outcomes, such as hypertension, kidney impairment,
and cognition loss.8 – 10 It will continue to be important in this
area.
Lead exposure has largely declined in the United States
over the last two decades; however, lead exposure and
toxicity in children remains a significant public health issue
because of heavy environmental pollution, especially due
to extensive usage of lead paint in housing, and hand-to-
mouth activities of toddlers. Research shows that children are
vulnerable to lead-induced subsymptomatic health effects,
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such as neurodevelopmental impairment and behavioral
disturbances, even at very low-level lead exposures.11,12
There are concerns regarding fetal lead exposure due to
lead transfer from maternal blood and bone. In addition,
lead exposure in the general population, especially in
children, continues to be a serious health threat in developing
countries.
Recently, gene-environmental interaction has become
significant for epidemiologic studies and researchers have
found that some people who carry certain types of genes may
be more susceptible to lead exposure than people who do
not carry these genes.13 Both past achievements and existing
issues with the epidemiology of lead toxicity render KXRF
technology as a valuable exposure assessment tool for the
present and for the future.
There are two types of bone lead measurement sys-
tems—the KXRF and the LXRF systems. The KXRF system,
which was more widely adopted in the x-ray laboratories
for bone lead measurement, is the technology that will be
discussed in the paper. The KXRF system has gone through
several improvements which include both hardware and
software upgrades. The sensitivity of the system has been
greatly improved since it was first used. On the one hand,
some researchers, such as epidemiologists, require improved
sensitivity, which provides an impetus towards improve-
ment; on the other hand, the improvement of the system has
made consistency of the data from the upgraded systems a
Copyright  2007 John Wiley & Sons, Ltd.
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concern for the researchers who rely on these data. There are
many factors that affect the data generated by these systems.
This paper summarizes most of the work published in this
area, and describes an intercalibration problem encountered
at the KXRF laboratory in Harvard School of Public Health
(HSPH). Since its establishment in 1981, the Harvard Metals
Epidemiology Research Group (MERG) has performed bone
lead measurements for thousands of patients using two types
of KXRF systems. A discrepancy was observed for the data
obtained by these two systems. A calibration problem with
one of the systems was brought to light by analyzing the
calibration lines and lead concentrations of standard phan-
toms. An adjustment is proposed to one set of data, and this
adjustment is verified by reference to a small group of data.
IMPACT OF KXRF DATA ON THE
EPIDEMIOLOGY OF LEAD TOXICITY
In the United States, lead remains a highly significant
environmental toxicant with regard to exposure to children
as well as a persistent occupational health problem for
thousands of workers. It also continues to be the focus of
intensive screening in pediatric and occupational medicine
clinics, and awareness, testing, and controls are increasing
throughout the developing world where industrialization
has occurred.
Research on lead toxicity has also intensified, in part
because of continued exposures, but in large measure due
to the recent insight that the full toxicologic implications
of lead exposure have yet to be appreciated because of
inadequate attention to long-term health effects related
to cumulative exposure (as opposed to acute effects of
short-term exposure). The significance of bone lead as a
biological marker of lead dose for adults has been reviewed
in some previous articles.3 In a recent mini-monograph
published in Environmental Health Perspectives, the journal of
the US National Institute for Environmental Health Sciences,
scientists who had participated in an expert national panel
observed that major recent progress has been made in
understanding the impact of cumulative lead exposure on
adult toxicity.14 It can be noted that much of this progress was
attributed to epidemiologic studies using KXRF instruments
to estimate cumulative lead burden in participating research
subjects15 which has allowed investigators to better detect
the impact of lead exposure on the risk of cardiovascular
disease16 and the decline of cognitive function.17
BONE LEAD AS A BIOMARKER IN THE
EPIDEMIOLOGY OF LEAD TOXICITY
In most of the epidemiologic studies of lead toxicity that
use KXRF measured bone lead as a biological marker,
measurements have been made on the mid-tibia bone, where
the target tissue is cortical bone which is well known
to accumulate lead in relation to fairly constant rates of
bone deposition and mineralization and very slow rates of
bone resoprtion.15 Such measurements essentially provide a
cumulative lead ‘dosimeter’ for each person, which, in turn,
has been shown in many recent studies to be superior to
blood lead levels (which mostly reflect recent exposure) in
predicting the individual risk of developing chronic ailments
like hypertension,8,18 – 20 accelerated declines in cognition,21
renal dysfunction,22 and cataracts.23
KXRF measurements have also been taken on bone sites
that are primarily of a trabecular nature, such as the patella or
the calcaneus. These bones have rates of bone turnover that
are much faster than that of cortical bone,15 and evidence
indicates that lead stores are much more mobilizable in
trabecular bone than in cortical bone.24
KXRF measured bone lead levels have also proved to
be of great value in understanding the potential impact on
fetal development of maternal bone lead stores. In a series
of studies conducted in Mexico City, investigators have
found that KXRF measured maternal bone lead levels predict
smaller infant weight at birth,25 shorter head circumference
and birth length,26 lower mental development scores when
offspring are at the age of two years,27 and greater risk of
maternal hypertension in the peripartum period.28
Although the number of laboratories with KXRF capa-
bility remains small, it seems clear that this technology is
here to stay. Not only does it have superb value in the many
on-going (and future) epidemiologic studies on lead toxicity,
but also it has clinical value, usually through its ability to do
retrospective dose assessment in individuals who are sus-
pected of having had chronic lead over-exposure but who
have lacked reliable blood lead levels in the past.
CONSISTENCY OF KXRF DATA GENERATED
BY UPDATED SYSTEMS OVERVIEW
KXRF bone lead measurement systems have made great con-
tributions to environmental epidemiologic studies of chronic
lead toxicity as described above. However, consistency of the
data obtained from KXRF systems is currently under greater
scrutiny. There are many factors that affect the data gener-
ated by in vivo KXRF bone lead measurement systems. These
factors can be grouped into three categories: (1) setup of the
system, or the hardware, (2) analysis of the data obtained
by the system, or the software, and (3) calibration of the
system. The following section will provide an overview of
these factors. Five versions of KXRF systems have been used
worldwide to measure bone lead, with relatively slight dif-
ferences between the versions amongst laboratories. The first
in vivo XRF measurement of lead in bone was performed by
Ahlgren et al. using a 57Co source in a 90° geometry. This
is the first generation measurement. Later, 109Cd induced
KXRF was found to yield superior results. The second gen-
eration of KXRF instruments included two types, one with
an annular 109Cd source mounted in front of the detector in
a 150–160° backscattering geometry,29 – 32 and the other one
with a point 109Cd source mounted above the detector in
a 160–170° backscattering geometry.33,34 The latter version
was commercialized and manufactured for a limited period
of time (AbioMed, Inc.; Danvers, MA, USA). The third gen-
eration has a 109Cd point source mounted centrally in front
of a larger detector in a 180° backscattering geometry.35 This
system uses a relatively large detector to offset the loss of
signals that results from having the source holder mounted
in front of the detector. This is the version that is currently
used in most KXRF laboratories. The fourth generation KXRF
Copyright  2007 John Wiley & Sons, Ltd. X-Ray Spectrom. 2008; 37: 69–75
DOI: 10.1002/xrs
In vivo K x-ray fluorescence of Pb in bone 71
instrument has a 109Cd point source mounted in front of an
array of four detectors at a 180° backscattering geometry,36,37
which affords a significant advance in sensitivity. The 57Co
system has only been consistently used by one laboratory
because of its lower sensitivity, and most of the epidemi-
ology and toxicology studies of the last 15 years have been
carried out with 109Cd systems. Thus, only the 109Cd systems
will be discussed further in this paper.
The spectra produced by 109Cd systems have several fea-
tures in common (Fig. 1). There are several lead characteristic
K x-ray peaks, with a large Compton background overlap-
ping with them. The Compton peak varies between 65.5 and
67 keV depending on the slightly different backscattering
angles. There are four factors in the system setup category
that will affect the precision of the calculated lead concentra-
tion results: characteristics of the detector(s), geometry of the
setup, source dimension and strength, and source holder’s
dimension, types of electronics used and setup of the elec-
tronics. These issues have been described in many papers
and will not be reviewed in detail here.32,38 – 42 Two main
versions of the data analysis programs for signal extraction
are involved in calculating the lead concentration once the
spectra are collected. The Marquardt algorithm is used by
most of the uncommercialized systems whereas the com-
mercial system (Abiomed, Inc) uses a baseline construction
algorithm
The type of data analysis program can affect both the
accuracy and precision of the result. This will be illustrated
in some detail in the following sections. System calibration
is one of the essential steps in the calculation of the
lead concentration of an unknown sample. Plaster of Paris
phantoms have been used as standard samples for system
calibration in most of the bone lead KXRF laboratories. Three
factors affect the accuracy and precision of the result in the
system calibration process: matrix correction, accuracy of
the lead concentration in the phantoms, and understanding
and handling of the intercept of the calibration lines.
The principle of matrix correction has been described in
detail by Todd43 and a calibration issue regarding this
subject has been discussed by Nie et al.44 This paper will
concentrate on challenges relating to system calibration using
phantoms, with a particular emphasis on the need to secure
accurate independent analysis of the lead concentration in
the phantoms in order to use these phantoms to determine
absolute concentrations of lead in human subjects. There
will also be a brief description of the issues involved in
calculating the lead concentration, and the data analysis
program (with a focus on programs using the baseline
construction algorithm). The handling of the intercept of the
calibration lines has been explained in detail in Todd’s paper
and will not be repeated in this paper.33 In summary, the
following section will be devoted to two issues regarding the
methodology of the KXRF bone lead measurement systems
that were not clarified in previous papers. The discussion
will be based on the data that were collected in the KXRF
systems at the Harvard School of Public Health.
INTERCALIBRATION OF COMMERCIAL AND
NONCOMMERCIAL KXRF SYSTEMS AT THE
HARVARD SCHOOL OF PUBLIC
HEALTH — SPECTRAL ANALYSIS AND
SYSTEM CALIBRATION
Since its establishment in 1991, the Harvard MERG
(http://www.hsph.harvard.edu/merg) has performed bone
lead measurements on thousands of subjects using KXRF
systems. Two systems have been involved. One is a second
generation commercialized AbioMed system with a 109Cd
source mounted above the detector, and the other is a third
generation system, which is a system with a 109Cd source
mounted in front of the detector. The spectral analysis pro-
grams and system calibration procedures are different for
these two types of systems, which are to be addressed when
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Figure 1. Spectrum for 109Cd KXRF lead measurement.
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SPECTRAL ANALYSIS PROGRAMS
The algorithm used in the AbioMed system for peak
extraction is termed the baseline construction and was
developed by the ABIOMED group.45 The idea is to construct
a baseline in the full energy peak region so that the number
of counts above this line (peak area) is a measure of the
intensity of the peak of interest. The theory involved in
this algorithm has been described in other papers.46,47 In
bone lead measurements, the peaks of interest include the
coherent peak and the K˛ and Kˇ peaks. For the coherent
peak, a linear baseline was constructed. Four channels from
the left side of the peak and four channels from the right
side of the peak were selected to calculate the average
background counts per channel; the net peak counts are
the total counts minus the total background counts. For
the K˛ and Kˇ peaks, because of the peak being relatively
small compared to the huge Compton background, a linear
baseline is not accurate enough to estimate the background,
hence, a nonlinear baseline was constructed. The baseline
was formulated as (a C bx C cx2). The parameters a, b, and
c can be calculated by fitting a certain number of channels
on the left side and right side of the channels of the peak.
Again, the net peak counts are the total counts minus the total
background counts calculated from the nonlinear baseline.
In this method, the net peak area is sensitive to the number
of channels selected on the left and right side of the peak,
and to where the channels are located, especially when the
peak is having a large background. In addition, a variety of
interferences must be dealt with in extracting the net peak
area.45
As mentioned, the algorithm used to extract peaks
for most of the uncommercialized systems is based on
the Marquardt algorithm. The functions were originally
developed by the Birmingham group,48 using a published
version of the Marquardt algorithm.49 In this program,
the peak is fitted to an arbitrary function, which includes
all the known components in the peak. For example,
the coherent peak is known to contain background, the
coherent peak, Kˇ2 peaks, O, Ca, C, and P/S K and L
Compton scattering edges. These edges arise from Compton
scattering from bound electrons. The binding energy of the
electron involved sets a maximum limit for the distribution
of possible energies of the Doppler-broadened Compton-
scattered continuum. Therefore, an upper limit edge arises
at the energy corresponding to the full energy of the incident
photon (88.025 keV) minus, for example, the K shell binding
energy of oxygen (0.543 keV), that is at 87.492 keV. This
cannot be resolved from the other features listed above.
Thus, the function includes Gaussian peaks for coherent
and Kˇ2 peaks, an exponential part for the background, and
a complementary error function for the incomplete charge
collection for the Gaussian peaks and all the edges. The
detailed functions and components of all the peaks can be
found elsewhere.50 This algorithm describes the peaks with
components that are predicted theoretically and verified by
experiment; hence, the lead signal can be extracted with
a higher accuracy compared to the baseline construction
algorithm.
SYSTEM CALIBRATION
A unique feature of using 109Cd source and backscattering
geometry is that both ˛ and ˇ peaks can be normalized to
the coherent peak; hence, it is not necessary to correct for
tissue attenuation, geometry, and slight movement of the
subject.31 The calibration line is created by measuring a set
of lead doped plaster of Paris phantoms, and plotting the
˛/coh and ˇ/coh ratio vs lead concentration. The subject or
patient’s bone lead concentration can then be calculated from
the ˛/coh and ˇ/coh ratio for the bone lead spectrum of the
subject and the intercept and slope of the calibration line.
When the plaster of Paris matrix is solely CaSO4Ð2H2O, the
ratio between the coherent cross-section of the bone and that
of the phantoms, i.e. the matrix correction factor, is about
1.46 at the large scattering angles for the systems involved in
this paper. This has to be accounted for when calculating the
subject’s bone lead concentration.
There is only one calibration line for the AbioMed system,
which was created at the time when the system was built.
It was based on the measurements of a set of lead doped
phantoms, and the (˛1 C ˇ1 C ˇ3)/coh ratio was used instead
of ˛1/coh and ˇ1/coh. The concentration of the subject or
patient’s bone lead is calculated as:
concentration D 1.46 ð ˛1 C ˇ1 C ˇ3
coh
/0.00490
where 1.46 is the converting factor, and 0.00490 is the slope
of the calibration line. The slope (0.00490) is fixed in the
program.
For the systems other than AbioMed system (noncom-
mercial systems), two calibration lines, one for the ˛1 peak
and one for the ˇ1 peak, were created. A set of lead doped
phantoms were measured and the ˛1/coh and ˇ1/coh ratios
vs Pb concentrations are plotted. The slopes and intercepts
of the calibration lines were used to calculate the lead con-
centration. The final result is the inverse variance weighted
mean of the concentrations from ˛1 and ˇ1 calibrations,
where the concentrations were weighted inversely by their
own variances.51
The phantoms used to calibrate the AbioMed system were
made by the ABIOMED group.45 These phantoms were used
only once for system calibration during manufacture, as the
calibration line was then fixed in the program. The phantoms
used for calibrating noncommercial systems were made
by the Chemistry laboratory at Harvard School of Public
Health.34 The Pb concentrations of these nine phantoms were
calculated at the time of manufacture, which is known as the
nominal value. The concentrations were then measured by
ICP-MS (ELAN-5000) in 1993, and the calibration lines were
calculated based on these values for the noncommercial
systems. The average and standard deviation of the slopes
are 0.00319 and 0.00003 for the ˛1 peak, and 0.00069 and
0.00002 for the ˇ1 peak, respectively for all the calibration
lines created by one of the systems. The average and standard
deviation of the intercepts are 0.003 and 0.003 for the ˛1 peak,
and 0.0007 and 0.0006 for the ˇ1 peak, respectively.
In order to compare with the AbioMed system, the slope
for the ˛1 C ˇ1 C ˇ3 was calculated from the intensities of
these peaks for the noncommercial systems, which give a
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slope of 0.00425. This value differs from the AbioMed value
by a factor of 0.87 and this factor is significantly different
to 1.0. As the intercepts of the calibration lines are close
to 0 ppm, significant lead contamination of the phantoms
can be ruled out. The most likely cause is that there is
some problem with the lead concentrations in the phantoms.
It happens that the lead concentrations in the phantoms
were measured by ICP-MS (ELAN-6100) again in 2004. The
nominal values and the values obtained in 1993 and 2004
by ICP-MS for lead concentrations in phantoms are listed
in Table 1. A regression line was plotted for the nominal
values vs the 1993 ICP-MS values. It has a high correlation
coefficient (1  r2 D 2.0 ð 104) and a slope of 0.885 š 0.005
with a small intercept of 0.28. The regression line of the
nominal values vs the 2004 ICP-MS values also has a high
correlation coefficient (1  r2 D 3.0 ð 104) and a slope close
to 1 (1.030 š 0.006) with a small intercept of 0.61. Therefore,
if we use either the nominal lead concentrations, or the 2004
ICP-MS values to perform the calibration, the calibration line
for the AbioMed system and the noncommercial systems will
be consistent. So the AbioMed system, the nominal phantom
concentrations and the 2004 ICP-MS agree with each other
and differ significantly from the 1993 ICP-MS values. The
high likelihood is that the factor of 0.87 is due to wrong lead
concentrations in phantoms obtained by ICP-MS in 1993.
In order to verify the above argument, i.e. the calibration
inconsistency is due to the wrongly measured lead con-
centrations in phantoms, some in vivo data were analyzed.
Forty five people had previously been measured by both the
AbioMed system and one of the noncommercial systems.
The bone lead concentration from the AbioMed system were







0.00 0.30 š 0.01 0.48 š 0.01
5.06 5.73 š 0.10 5.27 š 0.05
10.12 11.57 š 0.05 10.51 š 0.15
15.18 17.33 š 0.40 14.77 š 0.26
20.24 23.27 š 0.77 21.25 š 0.35
30.35 34.77 š 0.37 30.45 š 0.42
50.59 56.60 š 0.96 49.40 š 0.87
75.89 83.97 š 0.94 73.50 š 1.12
101.18 114.07 š 0.79 99.23 š 1.94
analyzed by the AbioMed program. The bone lead concen-
trations from the noncommercial system were analyzed by
the Marquardt program, with the calibration lines calculated
from the 1993 ICP-MS phantom lead concentration values.
There is a marginally significant difference that cannot be
explained by the statistical fluctuation between the data
obtained from the AbioMed system and that from the non-
commercial system. When the factor of 0.87 was applied to
adjust the noncommercial system, the data show no signif-
icant difference. In addition, the inverse variance weighted
(IVW) means of bone lead for this population obtained by
the two systems are significantly different before the adjust-
ment, and the difference disappeared after the adjustment.
The results are listed in Table 2.
CONCERNS WITH THE ABOVE CALIBRATION
PROBLEM FOR EPIDEMIOLOGY STUDIES
The AbioMed system was used before 1999 and the
noncommercial systems were used after 1999. As the bone
lead measurement data obtained by these systems have been
and will continue to be used in several large epidemiology
studies, the immediate concern is how the unadjusted data
obtained from the noncommercial systems will affect the
conclusion from these studies. For the upcoming studies and
data analysis, adjusting the post-1999 value by a factor of 0.87
will make the pre-1999 and post-1999 data consistent, hence
there is no effect of unadjusted post-1999 data for these
studies. As for the past studies, there are three possible
circumstances. In the first circumstance, the study only
involved the pre-1999 data. In this case, there is no effect
to any conclusion as the post-1999 data were not included
in the study. The second circumstance is that the study
only involved the post-1999 data. In this case; the effect
is that the absolute lead concentration of an individual
would be shifted by about 10%. However, this shift makes
absolutely no difference to conclusions with subjects having
higher and lower lead concentrations within the study. It
therefore makes no difference to the interpretation on the
relationship between bone lead concentration (exposure)
and a certain disease (outcome). The third circumstance is
a study involving both pre-1999 and post-1999 data. In this
case, if there is a true relationship between bone lead and
outcome, the unadjusted post-1999 data would most likely
weaken this relationship, because the data would be more
scattered with a10% higher Pb concentration for some of the
subjects distributed randomly with respect to outcome. In
Table 2. Lead concentration difference and Z-Scores with and without adjustment for the 45 subjects. The Z-Score is the
difference divided by the uncertainty in the difference. Ideally, the Z-Score should be distributed with a mean of zero and a





Average difference (ppm) 6.8 š 11.5 2.9 š 9.3
Z-Score 0.8 š 1.2 0.3 š 1.0
2 df D 78 2.11 (p D 0.0000) 1.01 (p D 0.4520)
IVW (inverse variance weighted) mean (ppm) AbioMed Noncommercial AbioMed Noncommercial
22.3 š 0.7 26.1 š 0.6 22.3 š 0.7 22.7 š 0.5
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other words, if the post-1999 data is adjusted and the analysis
carried out again, the relationship will be strenthened. If
there is no relationship between bone lead and outcome, the
unadjusted post-1999 data are unlikely to create an artificial
relationship, as the randomly distributed 10% bias is only
based on the exposure, i.e. bone lead, and should have no
effect on the outcome.
The epidemiologic scenario most problematic with
respect to a pre- and post-1999 shift would be if there were
an imbalance in the distribution of the outcome with respect
to pre- and post-1999, e.g. if there were a case-control design
and the cases were more likely to have been measured
pre-1999 and the controls were more likely to have been
measured post-1999. In such an example, a difference would
become apparent between the mean bone leads of the cases
and controls that were based on the bias rather than on true
biological differences.
COMMENTS ON THE CALIBRATION OF THE
KXRF BONE LEAD SYSTEM AND THE DATA
ANALYSIS PROGRAMS FOR THE SYSTEM
In principle, if there is no problem with the calibration,
two different KXRF bone lead measurement systems should
produce the same results within the uncertainties. Hence,
when there is a problem with the data consistency between
two systems, the first thing to check is the calibration of the
systems. Commonly seen issues with the calibration include
the inaccurate lead concentration values attributed to the
phantoms, which is the case in the above investigation,
unexpected compositions of the phantoms,44 and lead
contamination of the phantoms.33 Creating calibration lines
and examining the slopes and intercepts of the lines is the
first step in investigating these problems.
The AbioMed system has only been calibrated once.
This has an advantage in that the calibration line is not
phantom dependent, i.e. as long as this calibration is fine,
there will be no big problem with the results for the in vivo
measurement if the system is stable. The disadvantage is that
it cannot catch minor systematic changes in the calibration
for the system, which could make a small difference for
the in vivo results. (In practice, two noncommercial systems,
which are calibrated regularly, do not show a significant
variation in the calibration. So this factor is unlikely to have
caused any significant problems with the data from the
commercial system.) The problem will be more evident for
a more sensitive system. In addition, the calibration line of
the AbioMed system has no intercept. It is fine in principle;
however, it is not completely practical, as there are many
factors that can create an intercept. The intercept was not
considered in the adjustment for the pre-1999 and post-
1999 values for two reasons. Firstly, we do not really know
the intercept for the calibration line for the AbioMed system;
secondly, the magnitude of the difference is small, and can be
neglected when compared to the relatively high uncertainties
of both systems. The intercept of ¾1–2 ppm is not a big
problem for a system with a minimum detection limit of
6–10 ppm, but it will make some difference to the result for
a system with a minimum detection limit of 2–3 ppm, which
has been developed recently.37 In that case, we may want
to know more about the cause of the intercept. The possible
causes of the intercept are described elsewhere.33,52
As for the data analysis process, the software used to
analyze the data may not be the same, or people may use
different versions of the same software. On the basis of the
analysis of the data from the 45 subjects, the AbioMed
program and the Maquardt program did not make a
significant difference to the results. If the system is more
sensitive than the ones used in the Harvard MERG group,
different softwares may cause significant differences for the
results. Even with the most updated software, there may
still be some flaws.53 Since there is no strict standard for
these issues, researchers in New York State Department of
Health and the Mount Sinai School of Medicine are in the
process of finding a way to standardize the whole procedure
by organizing a bone lead standardization program (BLSP).
They sent the same set of bones from lead-fed goats to most
of the KXRF laboratories around the world. These bones will
be measured by a more sensitive and standardized method
after they are measured in each of these KXRF laboratories.
By comparing the KXRF results and the results from the
more standardized method, we will find out if there is a
problem with the whole procedure for all the laboratories.
If it is possible, one solution for the standardization would
be for all the laboratories to use the phantoms produced
by the same laboratory with the same material for system
calibration, use the same software to do the data analysis,
and follow the same measurement protocol.
SUMMARY AND CONCLUSION
The KXRF bone lead measurement technique has made great
contributions to epidemiologic studies of lead toxicity and
it will continue be a valuable exposure assessment tool in
this field. Driven by the requirements of its application,
this technique has been and is still in the process of being
improved. On the one hand, the improvement of technology
will provide more valuable data for the epidemiologic
studies; on the other hand, the upgraded systems have
induced some problems and concerns about the consistency
of the data. A great deal of work has been done in
standardizing the KXRF bone lead measurement method,
and more work in this area is expected.
Acknowledgements
The research described in this paper was supported primarily by
NIEHS R01-ES05257, R01-ES10798, R01-ES07821, and NIEHS Center
Grant P30-ES00002. Test subjects were evaluated for measurement
of bone lead levels in the outpatient Clinical Research Center
of the Brigham and Women’s Hospital with support from NIH
grant no. NCRR GCRC M01RR02635. The KXRF instrument used in
some of this work was developed by ABIOMED, Inc., of Danvers,
Massachusetts, with support from NIH grant no. SBIR 2R44 ES03918-
02. The authors would like to thank Mr Steve Oliveira and Dr Chitra
Amarasiriwardena for their assistance in acquiring the data and
information involved in the project.
REFERENCES
1. Ahlgren L, Lidén K, Mattson S, Tejning S. Scand. J. Work Environ.
Health 1976; 2: 82.
2. Hu H, Milder FL, Burger DE. Environ. Res. 1989; 49: 295.
Copyright  2007 John Wiley & Sons, Ltd. X-Ray Spectrom. 2008; 37: 69–75
DOI: 10.1002/xrs
In vivo K x-ray fluorescence of Pb in bone 75
3. Hu H, Rabinowitz M, Smith D. Environ. Health Perspect. 1998;
106: 1.
4. Silbergeld EK, Sauk J, Somerman M, Todd A, McNeill F,
Fowler B, Fontaine A, van Buren J. Neurotoxicology 1993; 14: 225.
5. Ambrose TM, Al-Lozi M, Scott MG. Clin. Chem. 2000; 46: 1171.
6. Schroeder HA, Tipton IH. Arch. Environ. Health 1968; 17: 965.
7. Nilsson U, Attewell R, Christoffersson J-O, Schütz A, Ahlgren L,
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